NasdaqCM:CELCBiotechs
Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval
Celcuity stock has delivered a very large 3 year return, yet its recent pullback and a mixed set of valuation checks raise questions about how much of the good news around its newly approved breast cancer therapy is already reflected in the price.
Over the last 3 years Celcuity has returned roughly 7x, which sets a high bar for further gains given how much value has already been created for existing shareholders.
The full FDA approval of REVTORPYK for advanced HR positive, HER2 negative...